Hypertrophic cardiomyopathy (HCM)
Cardiomyopathy · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Genetic (usually sarcomeric) LV hypertrophy not explained by loading conditions, often with dynamic LV outflow tract (LVOT) obstruction, diastolic dysfunction and risk of sudden cardiac death. Spans asymptomatic through exertional syncope, angina, dyspnoea and arrhythmia.
Red flags
- Unexplained syncope (exertional) — high SCD risk marker
- Family history of sudden cardiac death
- Documented NSVT or sustained VT
- Massive LVH (>=30 mm), apical aneurysm, extensive LGE on MRI
- Abnormal (flat/fall) BP response on exercise
- New AF with haemodynamic collapse
Assessment
Differential diagnosis
- Hypertensive / athlete's heart hypertrophy
- Aortic stenosis / subaortic membrane
- Cardiac amyloidosis and other infiltrative/storage diseases (Fabry, Danon)
- Hypertrophy from AS
- Mitochondrial / syndromic cardiomyopathy
Investigations
- Echocardiogram — LV wall thickness >=15 mm (>=13 mm with family history/genetics), SAM of mitral valve, LVOT gradient (rest + Valsalva/exercise; obstruction if >=30 mmHg, severe >=50 mmHg)
- ECG (LVH, deep T-wave inversions, pathological Q waves)
- Cardiac MRI — wall thickness, late gadolinium enhancement (fibrosis, SCD risk)
- Ambulatory ECG (48 h+) for NSVT
- Exercise test with BP response and provocable gradient
- Genetic testing and family screening (first-degree relatives); SCD risk stratification (ESC HCM Risk-SCD / AHA risk markers)
Management
- Confirm phenotype and exclude phenocopies (amyloid, Fabry, athlete's heart)
- Stratify sudden death risk (family history SCD, unexplained syncope, massive LVH >=30 mm, NSVT, apical aneurysm, extensive LGE, abnormal exercise BP) and offer ICD where high risk
- For symptomatic obstructive HCM: start negative inotropes to reduce gradient; AVOID vasodilators, nitrates, high-dose diuretics and digoxin which worsen obstruction
- Add disopyramide or a cardiac myosin inhibitor (mavacamten/aficamten) if beta-blocker/verapamil insufficient
- Refer for septal reduction therapy (surgical myectomy or alcohol septal ablation) if drug-refractory severe obstruction
- Manage AF — low threshold to anticoagulate (CHA2DS2-VASc less applicable; AF in HCM is high-risk) and restore rhythm
- Advise against intense competitive/burst exertion and ensure maintained hydration; family cascade screening
Drugs & doses
Bisoprolol 1.25-2.5 mg PO once daily, uptitrate (or metoprolol) — first-line negative inotrope for symptomatic LVOT obstruction
Verapamil 40 mg PO TDS, uptitrate to max ~480 mg/day (alternative if beta-blocker not tolerated; avoid in severe obstruction/hypotension)
Disopyramide 100-150 mg PO BD-TDS (add-on negative inotrope for obstruction) [monitor QT, anticholinergic effects]
Mavacamten 5 mg PO once daily, echo-guided titration 2.5-15 mg (cardiac myosin inhibitor for symptomatic obstructive HCM; REMS/monitoring for LVEF) [verify local availability]
Aficamten 5 mg PO once daily, titrate every 2-8 wk by 5 mg to max 15-20 mg per label (newer myosin inhibitor) [verify availability]
Anticoagulation for AF: apixaban 5 mg PO BD (DOAC acceptable in non-valvular HCM AF)
AVOID in obstructive HCM: GTN/nitrates, ACEi/ARB vasodilators, dihydropyridine CCBs, high-dose diuretics, digoxin (all can worsen gradient)
Cautious small fluid bolus for hypotension from dynamic obstruction (preload-dependent); phenylephrine (pure alpha, no inotropy) if pressor needed
Disposition
Specialist inherited-cardiac-conditions clinic with family screening; admit for syncope, arrhythmia or decompensation. High-risk patients for ICD; drug-refractory obstruction for septal reduction.
Complications & pitfalls
- Sudden cardiac death (ventricular arrhythmia)
- Atrial fibrillation and stroke
- Progression to end-stage 'burnt-out' dilated phase / heart failure
- Dynamic LVOT obstruction causing syncope/shock
- Infective endocarditis (obstructive HCM)
Exam pearls
- Mavacamten (EXPLORER-HCM) and aficamten (SEQUOIA-HCM) are cardiac myosin inhibitors that reduce LVOT gradient and symptoms — endorsed in the 2024 AHA/ACC HCM guideline as second-line for obstructive HCM; require echo LVEF monitoring.
- In obstructive HCM, a hypotensive patient needs PRELOAD and AFTERLOAD, not vasodilators or inotropes — fluids and phenylephrine, never GTN/dobutamine.
- Always exclude amyloidosis and Fabry before labelling 'HCM'.
- SCD risk, not symptoms, drives ICD decisions — use the ESC HCM Risk-SCD calculator / AHA major risk markers and screen families.
- Avoid competitive high-intensity sport; dehydration and vasodilatation (hot showers, alcohol, GTN) can trigger syncope.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.